|Articles|May 6, 2003
Robotically implanted, bioengineered microfistula shows promise as innovation for glaucoma drainage surgery
Ft. Lauderdale-Robotic biological microfistula implantation appears to be a reliable and controllable way to produce a scleral channel between the anterior chamber and subconjunctival space based on animal trials.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
2
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
3
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA
4
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%
5











































.png)


